目的 观察白眉蛇毒血凝酶联用酚妥拉明治疗肺结核咯血的临床效果.方法 将76例肺结核咯血患者随机分为治疗组40例和对照组36例,治疗组采用白眉蛇毒血凝酶静脉注射联用酚妥拉明静滴,对照组采用脑垂体后叶素持续静脉泵入.观察两组患者72 h内疗效和不良反应.结果 治疗组显效率为85.0％,总有效率为95.0％;对照组显效率为72.22％,总有效率为74.99％.两组显效率比较,差异无统计学意义(P＞0.05);但总有效率比较差异有统计学意义(P＜0.05).治疗组不良反应发生率为7.5％,对照组为77.8％,差异具有统计学意义(P＜0.05).结论 白眉蛇毒血凝酶联用酚妥拉明治疗肺结核咯血临床疗效明显,副作用少,是治疗肺结核咯血的较为理想有效药物.%Objective To study the clinical effect of hemocoagulase combined with phentolamine in the treatment of patients with hemoptysis in tuberculosis. Methods Seventy-six patients with hemoptysis in tuberculosis were randomly divided into the study group and the control group. Patients in the study group (n=40) were treated with intravenous injection of hemocoagulase combined with intravenous drip of phentolamine as maintenance dose. Patients in the control group (n=36) were treated with pumping pituitary continuously. The effect and adverse reactions was observed during 72 hours. Results The total effective rate was 95.0% in the study group and 74.99% in the control group, showing statistically significant difference between the two groups (P<0.05). The excellent and good rate was 85.0% in the study group and 72.22% in the control group, showing no statistically significant difference between the two groups (P>0.05). The incidence of adverse reactions was 7.5% in the study group, significantly lower than 77.8% in the control group (P<0.05). Conclusion Hemocoagulase combined with phentolamine is effective for treating hemoptysis in tuberculosis with less side effects, which is regarded as an ideal treatment for hemoptysis.
展开▼
